Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arylacenamide refers to a class of compounds, specifically small arylamide foldamers, which are designed to mimic the amphiphilic nature of antimicrobial peptides (AMPs). These compounds exhibit potent bactericidal activity against both Gram-negative and Gram-positive bacterial strains. Their mechanism of action involves causing significant changes in the permeability of the bacterial outer membrane and more limited permeabilization of the inner membrane, ultimately leading to bacterial cell death. Additionally, they compromise protein secretion into the periplasm and outer membrane of bacteria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Arylacenamide.